RU2728858C2 - Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью - Google Patents

Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью Download PDF

Info

Publication number
RU2728858C2
RU2728858C2 RU2017134043A RU2017134043A RU2728858C2 RU 2728858 C2 RU2728858 C2 RU 2728858C2 RU 2017134043 A RU2017134043 A RU 2017134043A RU 2017134043 A RU2017134043 A RU 2017134043A RU 2728858 C2 RU2728858 C2 RU 2728858C2
Authority
RU
Russia
Prior art keywords
ser
seq
val
gly
thr
Prior art date
Application number
RU2017134043A
Other languages
English (en)
Russian (ru)
Other versions
RU2017134043A (ru
RU2017134043A3 (https=
Inventor
Хуавэй Цю
Джули БЕРД
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of RU2017134043A publication Critical patent/RU2017134043A/ru
Publication of RU2017134043A3 publication Critical patent/RU2017134043A3/ru
Application granted granted Critical
Publication of RU2728858C2 publication Critical patent/RU2728858C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2017134043A 2015-03-04 2016-03-03 Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью RU2728858C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128149P 2015-03-04 2015-03-04
US62/128,149 2015-03-04
PCT/US2016/020780 WO2016141245A1 (en) 2015-03-04 2016-03-03 Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity

Publications (3)

Publication Number Publication Date
RU2017134043A RU2017134043A (ru) 2019-04-05
RU2017134043A3 RU2017134043A3 (https=) 2019-08-29
RU2728858C2 true RU2728858C2 (ru) 2020-07-31

Family

ID=55524479

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134043A RU2728858C2 (ru) 2015-03-04 2016-03-03 Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью

Country Status (22)

Country Link
US (4) US11325970B2 (https=)
EP (3) EP4495137A3 (https=)
JP (1) JP6745275B2 (https=)
KR (3) KR102560072B1 (https=)
CN (1) CN107787329B (https=)
AR (1) AR103840A1 (https=)
AU (1) AU2016226098B2 (https=)
DK (1) DK3265487T3 (https=)
ES (2) ES2927297T3 (https=)
HR (1) HRP20221142T1 (https=)
HU (1) HUE059644T2 (https=)
IL (1) IL254239B2 (https=)
LT (1) LT3265487T (https=)
MX (1) MX382703B (https=)
PL (1) PL3265487T3 (https=)
PT (1) PT3265487T (https=)
RS (1) RS63589B1 (https=)
RU (1) RU2728858C2 (https=)
SG (2) SG10201908019UA (https=)
SI (1) SI3265487T1 (https=)
TW (1) TWI733661B (https=)
WO (1) WO2016141245A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI832600B (zh) 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
MX2022015304A (es) * 2020-06-12 2023-03-23 Bristol Myers Squibb Tgf Beta Inc Agentes de union al factor de crecimiento transformante beta (tgfbeta) y usos de los mismos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
EP1486560A3 (en) 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Specific antibodies and antibody fragments for TGFBETA1
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
EP1740615B1 (en) * 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
CN101084007A (zh) * 2004-09-22 2007-12-05 金齐姆公司 TGF－β拮抗剂限制免疫抑制剂肾毒性的用途
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
BRPI0608376A8 (pt) 2005-04-22 2018-10-16 Lilly Co Eli composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
EP1966243B1 (en) 2005-12-23 2012-02-15 Eli Lilly And Company Tgf-beta binding antibodies
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
JP4294082B2 (ja) 2006-03-23 2009-07-08 協和発酵キリン株式会社 ヒトトロンボポエチン受容体に対するアゴニスト抗体
MX2009003518A (es) * 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
WO2010124276A2 (en) * 2009-04-24 2010-10-28 Vanderbilt Universtiy Anti-tgf-beta induction of bone cell function and bone growth
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
IN2015DN01299A (https=) 2012-07-23 2015-07-03 Zymeworks Inc
LT2971048T (lt) 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
HRP20181939T4 (hr) * 2013-03-20 2022-05-13 Genzyme Corporation Postupci za liječenje osteogenesis imperfecta
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERRY M. J. et al., Substitution of cysteine for selenocysteine in type I iodothyronine deiodinase reduces the catalytic efficiency of the protein but enhances its translation, Endocrinology, 1992, V. 131, N. 4, p.1848-1852 *
CHEN C. et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations, The EMBO journal, 1995, V. 14, N. 12, p.2784-2794. *
COLMAN P. M., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 1994, V. 145, N. 1, p.33-36. *
GASSER B. et al., Antibody production with yeasts and filamentous fungi: on the road to large scale?, Biotechnology letters, 2007, V. 29, N. 2, p.201-212 *
KUSSIE P. H. et al., A single engineered amino acid substitution changes antibody fine specificity, The Journal of Immunology, 1994, V. 152, N. 1, p.146-152 *
RUDIKOFF S. et al., Single amino acid substitution altering antigen-binding specificity, Proceedings of the National Academy of Sciences, 1982, V. 79, N. 6, p.1979-1983. *
RUDIKOFF S. et al., Single amino acid substitution altering antigen-binding specificity, Proceedings of the National Academy of Sciences, 1982, V. 79, N. 6, p.1979-1983. COLMAN P. M., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 1994, V. 145, N. 1, p.33-36. KUSSIE P. H. et al., A single engineered amino acid substitution changes antibody fine specificity, The Journal of Immunology, 1994, V. 152, N. 1, p.146-152. CHEN C. et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations, The EMBO journal, 1995, V. 14, N. 12, p.2784-2794. BERRY M. J. et al., Substitution of cysteine for selenocysteine in type I iodothyronine deiodinase reduces the catalytic efficiency of the protein but enhances its translation, Endocrinology, 1992, V. 131, N. 4, p.1848-1852. GASSER B. et al., Antibody production with yeasts and filamentous fungi: on the road to large scale *
АЛЕКПЕРОВ Р. Т., Лечение системной склеродермии, Современная ревматология, 2011, V. 5, N. 3, с.18-24. *

Also Published As

Publication number Publication date
KR20240076851A (ko) 2024-05-30
KR20170120689A (ko) 2017-10-31
EP3265487A1 (en) 2018-01-10
JP2018512124A (ja) 2018-05-17
SI3265487T1 (sl) 2022-10-28
US12162933B2 (en) 2024-12-10
MX382703B (es) 2025-03-13
TW201706306A (zh) 2017-02-16
AU2016226098A1 (en) 2017-10-26
PT3265487T (pt) 2022-09-29
CA2978439A1 (en) 2016-09-09
IL254239B2 (en) 2023-06-01
ES2927297T3 (es) 2022-11-04
EP4495137A3 (en) 2025-03-26
EP4495137A2 (en) 2025-01-22
US20250179163A1 (en) 2025-06-05
CN107787329A (zh) 2018-03-09
US20240117028A1 (en) 2024-04-11
KR102560072B1 (ko) 2023-07-25
US11325970B2 (en) 2022-05-10
ES2994790T3 (en) 2025-01-31
SG11201707109XA (en) 2017-09-28
RU2017134043A (ru) 2019-04-05
EP4163299B1 (en) 2024-10-02
EP3265487B1 (en) 2022-06-29
US11834495B2 (en) 2023-12-05
EP4163299A1 (en) 2023-04-12
US20180044412A1 (en) 2018-02-15
WO2016141245A1 (en) 2016-09-09
US20220315649A1 (en) 2022-10-06
MX2017011252A (es) 2018-02-19
IL254239A0 (en) 2017-10-31
DK3265487T3 (da) 2022-09-26
KR102668864B1 (ko) 2024-05-27
TWI733661B (zh) 2021-07-21
CN107787329B (zh) 2021-08-24
EP4163299C0 (en) 2024-10-02
KR20230116946A (ko) 2023-08-04
AR103840A1 (es) 2017-06-07
JP6745275B2 (ja) 2020-08-26
RS63589B1 (sr) 2022-10-31
BR112017018678A2 (pt) 2018-04-17
HUE059644T2 (hu) 2022-12-28
RU2017134043A3 (https=) 2019-08-29
SG10201908019UA (en) 2019-10-30
AU2016226098B2 (en) 2021-11-25
PL3265487T3 (pl) 2023-01-23
HRP20221142T1 (hr) 2022-11-25
LT3265487T (lt) 2022-09-26

Similar Documents

Publication Publication Date Title
US12162933B2 (en) Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity
US12473356B2 (en) scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
HK40119111A (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40091838A (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40091838B (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
CA2978439C (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40117203A (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity
CA2978459C (en) Scfv-fc dimers that bind transforming growth factor-.beta.1 with high affinity, avidity and specificity
HK1249113B (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK1249113A1 (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity